We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current EBS market cap is 429.14M. The company's latest EPS is USD -14.0355 and P/E is -0.55.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 269.7M | 276.6M | 300.4M | 254.7M | 293.8M |
| Operating Income | -548.3M | -73.7M | 39.8M | -176.3M | 37.3M |
| Net Income | -266.7M | -49.5M | 9M | -283.1M | 114.8M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.11B | 1.56B | 1.79B | 1.12B | 1.05B |
| Operating Income | 114.1M | 433.8M | 352.6M | -172.7M | -726.4M |
| Net Income | 54.5M | 305.1M | 230.9M | -223.8M | -760.5M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.89B | 1.82B | 1.8B | 1.51B | 1.48B |
| Total Liabilities | 1.2B | 1.17B | 1.14B | 1.13B | 969.4M |
| Total Equity | 697.2M | 649.3M | 663.9M | 386.3M | 508.4M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.33B | 2.88B | 2.96B | 3.17B | 1.82B |
| Total Liabilities | 1.24B | 1.44B | 1.34B | 1.78B | 1.17B |
| Total Equity | 1.09B | 1.45B | 1.62B | 1.38B | 649.3M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -238.4M | -206.3M | -62.6M | -15.1M | 138.6M |
| Investing | 223.7M | 212.3M | -10.8M | -15.4M | 96.6M |
| Financing | -540.4M | -535.7M | 40.7M | -10.2M | -190.5M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 188M | 536M | 321.1M | -34.1M | -206.3M |
| Investing | -96.9M | -151M | -225M | -381.3M | 212.3M |
| Financing | -35.9M | 69.5M | -141M | 481.2M | -535.7M |
| Market Cap | 429.14M |
| Price to Earnings Ratio | -0.55 |
| Price to Sales Ratio | 0.4 |
| Price to Cash Ratio | 3.74 |
| Price to Book Ratio | 0.64 |
| Dividend Yield | - |
| Shares Outstanding | 54.18M |
| Average Volume (1 week) | 1.65M |
| Average Volume (1 Month) | 984.88k |
| 52 Week Change | 365.88% |
| 52 Week High | 15.10 |
| 52 Week Low | 1.66 |
| Spread (Intraday) | 0.23 (2.9%) |
| Company Name | Emergent Biosolutions Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.emergentbiosolutions.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
